Scientific program

Thursday, October 11, 2018

 09:00 – 12:20 Pre-Congress Workshop:
From concept to publication: Clinical trials in breast cancer
Hall A
 09:00 – 12:20 Pre-Congress Workshop:
Pathology – shades of grey: When the answer is non-definitive
Hall B
 09:00 – 12:20 Pre-Congress Workshop:
The challenging patient
Hall C
 12:20 – 13:20 Lunch break
 13:20 – 16:20 Pre-Congress Workshop:
Managing breast cancer in resource poor locations
Hall A
 13:20 – 16:20 Pre-Congress Workshop:
Radiation oncology
Hall B
 13:20 – 16:20 Pre-Congress Workshop:
The tortuous road to diagnosis
Hall C
 17:15 – 17:30 Congress Opening Hall A
 17:30 – 19:00 Plenary Session 1:
Neoadjuvant therapy
Hall A
Chairpersons Richard de Boer, Australia
Christobel Saunders, Australia
 17:30 – 18:00
17:30
17:40
17:50
Debate: That decisions regarding NAST should be based on TN stage rather than breast cancer subtype
TN stageBruce Mann, Australia
Breast cancer subtypes: Stephen Johnston, UK
Discussion
 18:00 – 18:30 The potential of neoadjuvant endocrine therapy
Mitch Dowsett, UK
 18:30 – 19:00
18:30
18:40
18:50
Debate: That further chemotherapy should be recommended for patients with ER-ve cancer not achieving pCR
Yes: Stacy Moulder, USA
No: Nicholas Wilcken, Australia
Discussion
 19:00 Networking Reception

Friday, October 12, 2018

07:00 – 08:30 Morning Industry Symposium:
Supported by Genomic Health
Breakfast will be served prior to the session
Hall A
07:00 – 08:30 Morning Industry Symposium:
Supported by Pfizer
Breakfast will be served prior to the session
Hall B
 08:30 – 09:30 Parallel Session 2:
Screening
Hall A
Chairpersons    
 08:30 – 09:10
08:30
08:45
09:00
Debate: That BreastScreen Australia requires urgent and radical reform
Yes: Alexandra Barratt, Australia
No: Bruce Mann, Australia
Discussion
 09:10 – 09:30 Mammographic density
Jack Cuzick, UK
 08:30 – 09:30 Parallel Session 3:
Keeping patients on their endocrine treatments
Hall B
Chairpersons Nicole McCarthy, Australia
Kerry Shanahan, Australia
 
08:30 – 08:50 The biology of endocrine side effects
Mitch Dowsett, Australia
08:50 – 09:05 Below the breast: Managing genitourinary symptoms
Martha Hickey, Australia
 09:05 – 09:30
09:05
09:15
09:25
Debate: How to best manage endocrine therapy symptoms: Pharma or sweat?
SWEAT: Liz Eakin, Australia
PHARMA: Fran Boyle, Australia
Discussion
 09:30 – 11:00 Plenary Session 4:
Genetics
Hall A
Chairpersons    
 09:30 – 10:00
09:30
09:40
09:50
Debate: That most patients with breast cancer should be panel tested for germline mutations
Yes: Paul James, Australia
No: Marion Harris, Australia
Discussion
10:00 – 10:30 The medical implications of panel testing: Platinums/PARPi’s
Rebecca Dent, Singapore
10:30 – 11:00
10:30
10:40
10:50
Debate: That gene carriers diagnosed with cancer should be strongly advised to undergo bilateral  mastectomy
Yes: TBA
No: Christopher Pyke, Australia
Discussion
 11:00 – 11:30 Coffee break and poster viewing
 11:30 – 12:30 Parallel Session 5:
Imaging
Hall A
Chairperson Belinda Yeo, Australia  
 11:30 – 11:50 Assessment of response to neoadjuvant chemotherapy
Clair Shadbolt, Australia
11:50 – 12:10 The promise of contrast imaging for breast cancer
Allison Rose, Australia
 12:10 – 12:30 PET in breast cancer
Kate Moodie, Australia
11:30 – 12:30 Industry Symposium:
Supported by Roche
Hall B
 11:30 – 12:30 Parallel Session 6:
Free Papers
Hall C
 12:30 – 13:30 Lunch break and poster viewing
 13:30 – 14:30 Plenary Session 7:
Controversies in reconstruction
Hall A
Chairpersons Elisabeth Elder, Australia
Andrew Spillane, Australia
 
 13:30 – 14:00
13:30
13:40
13:50
Debate: That neoadjuvant RT prior to TM/reconstruction is a better approach than post-mastectomy RT
Yes: Caroline Baker, Australia
No: Boon Chua, Australia
Discussion
 
14:00 – 14:30
14:00
14:10
14:20
Debate: That two-stage implant based reconstruction is rarely indicated
Yes: Sanjay Warrier, Australia
No: Dean Trotter, Australia
Discussion
13:30 – 14:30 Industry Symposium:
Supported by Novartis
Hall B
 13:30 – 14:30 Parallel Session 8:
Free Papers
Hall C
 14:30 – 15:50 Plenary Session 9:
Adjuvant endocrine therapy
Hall A
Chairperson Linda Vahdat, USA
14:30 – 14:40 What is the ER/PR threshold at which endocrine therapy should be prescribed, or may be relied upon?
Nirmala Pathmanathan, Australia
14:40 – 15:10
14:40
14:50
15:00
Debate: That topical oestrogens are an acceptable treatment in pts with HR+ve early breast cancer
Yes: Yoland Antill, Australia
No: Catherine Oakman, Australia
Discussion
15:10 – 15:20 Update on SOFT/TEXT
Prue Francis, Australia
15:20 – 15:50
15:20
15:30
15:40
Debate: That 10 years of AET is overtreatment
Yes: Janice Tsang, Hong Kong
No: Nicole McCarthy, Australia
Discussion
15:50 – 16:10 Coffee break and poster viewing
 16:10 – 17:30 Parallel Session 10:
Molecular assays
Hall A
Chairpersons Bruce Mann, Australia
Louis Chow,Hong Kong
 
16:10 – 16:25 The case for using Oncotype DX
Virginia Kaklamani, USA
16:25 – 16:40 The case for using Endopredict
Mitch Dowsett, UK
16:40 – 16:55 The case for using Mammaprint
Alastair Thompson, USA
16:55 – 17:10 The case for using Prosigna
Janice Tsang, Hong Kong
17:10 – 17:25 The case for rarely using an assay
Belinda Yeo, Australia
17:25 – 17:30 Discussion
 16:10 – 17:30 Parallel Session 11:
Life after breast cancer
Hall B
Chairperson Lesley Stafford, Australia
16:10 – 16:40 Risking another cancer: Who should have a mastectomy/CPM?
Laura Esserman, USA
16:40 – 17:00 Motivational interviewing: How to get the best lifestyle outcomes from your patients
Sarah Hardcastle, Australia
17:00 – 17:30 Brains (cognitive decline) and breast cancer
Adam Walker, Australia

Saturday, October 13, 2018

07:00 – 08:30 Morning Industry Symposium:
Supported by Eisai
Breakfast will be served prior to the session
Hall B
07:00 – 08:30 Morning Industry Symposium:
Supported by Endomag
Breakfast will be served prior to the session
Hall C
 08:30 – 09:30 Plenary Session 12:
DCIS
Hall A
Chairpersons Christopher Pyke, Australia
Yvonne Zissiadis, Australia
 
 08:30 – 09:00
08:30
08:40
08:50
Debate: That RT after WE for DCIS is usually overtreatment
Yes: Laura Esserman, USA
No: Lori Pierce, USA
Discussion
 09:00 – 09:20 Active surveillance is an option for low-risk DCIS
Christobel Saunders, Australia
09:20 – 09:30 Discussion
 08:30 – 09:30 Parallel Session 13:
Topics in chemotherapy
Hall B
Chairpersons  
 08:30 – 09:00
08:30
08:40
08:50
Debate: That dose-dense chemotherapy should be the standard for all subtypes of early breast cancer
Yes: Linda Vahdat, USA
No: TBA
Discussion
09:00 – 09:15 New strategies in early stage non-BRCA TNBC
Stacy Moulder, USA
09:15 – 09:30 Will NGS become a standard part of management of breast cancer?
Sarah-Jane Dawson, Australia
 09:30 – 11:00 Plenary Session 14:
Loco-Regional therapy
Hall A
Chairpersons
 09:30 – 10:00
09:30
09:40
09:50
Debate: That all patients with axillary nodal disease pre-NACT should have axillary dissection or radiation
Yes: Yvonne Zissiadis, Australia
No: Jane O’Brien, Australia
Discussion
 10:00 – 10:20 The implications of the AMAROS study
Lori Pierce, USA
10:20 – 11:00
10:20
10:35
10:50
Debate: That regional nodal radiation is appropriate for most patients with nodal disease
Yes: Reshma Jagsi, USA
No: Louis Chow, Hong Kong
Discussion
11:00 – 11:30 Coffee break and poster viewing
 11:30 – 13:00 Plenary Session 15:
Local therapy
Hall A
Chairpersons
 11:30 – 12:00
11:30
11:40
11:50
Debate: Margins: That “no tumour on ink” is a dangerous over-simplification
Yes: Ian Campbell, New Zealand
No: Raghu Ram, India
Discussion
 12:00 – 12:30 The status of intra-operative techniques for localization/margin assessment
Alistair Thompson, USA
12:30 – 13:00
12:30
12:40
12:50
Debate: That IORT is ready for prime time
Yes: Dennis R. Holmes, USA
No: Michael Chao, Australia
Discussion
11:30 – 13:00 Industry Symposium: Key issues around bone health
Supported by Amgen
Hall B
10:30 – 13:00 Breast Cancer Network Australia: Metastatic breast cancer
Hall C
13:00 – 14:00 Lunch break and poster viewing
 14:00 – 15:00 Parallel Session 16:
Exercise and lympoedema
Hall A
Chairperson
14:00 – 14:20 Surgery for lymphoedema: A new paradigm
Ramin Shayan, Australia
14:20 – 14:40 Prescribing exercise and putting it into practice
Prue Cormie, Australia
14:40 – 14:50 Wearable technology and influencing health behaviours
Sarah Hardcastle, Australia
14:50 – 15:00 Discussion
 14:00 – 15:00 Parallel Session 17:
CNS metastases
Hall B
Chairpersons  
14:00 – 14:20 Molecular pathology of CNS metastases
Sunil R. Lakhani, Australia
14:20 – 14:40 Local therapy for CNS metastases: The roles of surgery, SRS and WBRT in 2018
Claire Phillips, Australia
14:40 – 15:00 Drug treatment for CNS metastasis
Arlene Chan, Australia
 14:00 – 15:00 Plenary Session 18:
Breast surgery
Hall c
Chairpersons
14:00 – 14:15 Onco-anaesthesia: Is anaesthetic technique a risk factor for outcome?
Bernhard Riedel, Australia
 14:15 – 14:45
14:15
14:25
14:35
Debate: That percutaneous ablation is a useful treatment option in early breast cancer
Yes: Dennis Holmes, USA
No: Andrew Spillane, Australia
Discussion
 14:45 – 15:00 How should quality of life be assessed after breast cancer surgery
Elizabeth Elder, Australia
 15:00 – 16:15 Parallel Session 19:
Breast Cancer 2025
Hall A
Chairpersons Christobel Saunders, Australia
Yvonne Zissiadis, Australia
 
15:00 – 15:15 Prevention: BRCA-D,P
Geoffrey Lindeman, Australia
15:15 – 15:30 Pathology
Sunil R. Lakhani, Australia
15:30 – 15:45 Medical oncology: Will immunotherapy ever be a major part of breast cancer treatment?
Sherene Loi, Australia
15:15 – 16:00 Surgery
Laura Esserman, USA
16:00 – 16:15 Radiation oncology
Reshma Jagsi, USA
16:15 – 16:30 Congress closing and Award presentation
Hall A
Chairpersons Christobel Saunders, Australia
Yvonne Zissiadis, Australia
Bruce Mann, Australia